Publication:
Therapeutic drug monitoring of immunosuppressant drugs in Marmara University Hospital

Simple item page
dc.contributor.authorAKICI, AHMET
dc.contributor.authorsKaraalp, A; Demir, D; Goren, MZ; Akici, A; Iskender, E; Yananli, HR; Ozyurt, H; Ozkaynakci, A; Berkman, K; Oktay, S; Onat, F
dc.date.accessioned2022-03-12T17:16:22Z
dc.date.available2022-03-12T17:16:22Z
dc.date.issued2004
dc.description.abstractImmunosuppressive therapy is the most crucial treatment of organ-transplanted patients. Both cyclosporin and tacrolimus have become a part of the standard immunosuppressive therapy for prevention of rejection. However, lower levels of these drugs are associated with insufficient therapy and eventually result in rejection of the organ, and, on the contrary, higher levels are associated with toxicity to certain organs such as liver and kidneys. Therefore, the levels of these drugs in body fluids should be monitored for the prevention of unwanted situations. In this retrospective study, the authors evaluated the 18-month profile of blood drug concentrations of cyclosporin and tacrolimus in patients admitted to the TDM Unit of the Marmara University Hospital (Istanbul, Turkey) between June 2000 and November 2001. A total of 578 blood samples (347 cyclosporin and 231 tacrolimus) from 134 patients (88 for cyclosporin, 46 for tacrolimus) were evaluated in this period. The therapeutic trough ranges were accepted as 100-350 ng/mL for cyclosporin and 5 20 ng/mL for tacrolimus, and levels below or above the identified levels were accepted to be subtherapeutic or toxic. Most of the results were found within the range of therapeutic levels (67.48% for cyclosporin and 82.71% for tacrolimus). Subtherapeutic levels were found in 19.92% of all cyclosporin and 10.53% of all tacrolimus assays, whereas toxic levels were seen in 12.60% and 6.77% of cyclosporin and tacrolimus results, respectively. In conclusion, this study gives information about the TDM practice in institutional clinical laboratory and also indicates the importance of critical information such as sampling time for individual decision making in dosage regiment.
dc.identifier.doi10.1097/00007691-200406000-00007
dc.identifier.eissn1536-3694
dc.identifier.issn0163-4356
dc.identifier.pubmed15167625
dc.identifier.urihttps://hdl.handle.net/11424/227542
dc.identifier.wosWOS:000222196600006
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofTHERAPEUTIC DRUG MONITORING
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectcyclosporin
dc.subjectimmunosuppressant
dc.subjecttacrolimus
dc.subjecttherapeutic drug monitoring
dc.subjectCYCLOSPORINE
dc.subjectPHARMACOKINETICS
dc.subjectTRANSPLANTATION
dc.subjectRECIPIENTS
dc.subject2-HOUR
dc.subjectTROUGH
dc.titleTherapeutic drug monitoring of immunosuppressant drugs in Marmara University Hospital
dc.typearticle
dspace.entity.typePublication
local.avesis.idae926fd8-ab41-4f7f-9f80-cf84b1f78562
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages4
oaire.citation.endPage266
oaire.citation.issue3
oaire.citation.startPage263
oaire.citation.titleTHERAPEUTIC DRUG MONITORING
oaire.citation.volume26
relation.isAuthorOfPublication6c7c9f26-63a9-4f6f-91cd-aa9e3452919c
relation.isAuthorOfPublication.latestForDiscovery6c7c9f26-63a9-4f6f-91cd-aa9e3452919c

Files

Collections

Research Outputs